Fox Run Management L.L.C. Raises Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Fox Run Management L.L.C. lifted its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 67.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 68,040 shares of the biotechnology company’s stock after purchasing an additional 27,406 shares during the quarter. Fox Run Management L.L.C.’s holdings in BioCryst Pharmaceuticals were worth $512,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Geode Capital Management LLC raised its position in BioCryst Pharmaceuticals by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock worth $36,776,000 after buying an additional 127,708 shares during the last quarter. Fisher Asset Management LLC grew its stake in shares of BioCryst Pharmaceuticals by 16.9% in the third quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after acquiring an additional 481,359 shares during the period. Two Sigma Advisers LP raised its holdings in shares of BioCryst Pharmaceuticals by 13.6% during the third quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock valued at $16,576,000 after purchasing an additional 261,500 shares during the last quarter. FMR LLC lifted its position in BioCryst Pharmaceuticals by 2.4% during the third quarter. FMR LLC now owns 1,988,389 shares of the biotechnology company’s stock valued at $15,112,000 after purchasing an additional 46,110 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in BioCryst Pharmaceuticals by 4.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company’s stock worth $14,890,000 after purchasing an additional 91,998 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ:BCRX opened at $8.07 on Wednesday. The company has a market capitalization of $1.69 billion, a P/E ratio of -13.23 and a beta of 1.85. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $9.50. The firm’s 50 day simple moving average is $8.14 and its two-hundred day simple moving average is $7.82.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. During the same quarter last year, the business posted $0.28 EPS. The business’s quarterly revenue was up 40.8% compared to the same quarter last year. On average, sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BCRX has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Evercore ISI increased their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Royal Bank of Canada restated an “outperform” rating and set a $11.00 price target (up from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Needham & Company LLC increased their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Finally, Wedbush assumed coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 target price for the company. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $15.57.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.